Free Trial

Bicycle Therapeutics (NASDAQ:BCYC) Shares Down 4.6% - Here's What Happened

Bicycle Therapeutics logo with Medical background

Shares of Bicycle Therapeutics plc (NASDAQ:BCYC - Get Free Report) dropped 4.6% during trading on Friday . The stock traded as low as $8.27 and last traded at $8.29. Approximately 45,076 shares traded hands during trading, a decline of 88% from the average daily volume of 388,414 shares. The stock had previously closed at $8.69.

Wall Street Analyst Weigh In

BCYC has been the topic of several research reports. JMP Securities decreased their price target on shares of Bicycle Therapeutics from $26.00 to $22.00 and set a "market outperform" rating on the stock in a research note on Friday, May 2nd. Royal Bank of Canada cut their price target on shares of Bicycle Therapeutics from $35.00 to $32.00 and set an "outperform" rating on the stock in a report on Friday, May 2nd. HC Wainwright reiterated a "buy" rating and issued a $33.00 price target on shares of Bicycle Therapeutics in a report on Wednesday, February 26th. Morgan Stanley set a $17.00 price objective on Bicycle Therapeutics and gave the company an "equal weight" rating in a research report on Monday, May 5th. Finally, Needham & Company LLC reissued a "buy" rating and set a $29.00 price objective on shares of Bicycle Therapeutics in a research report on Friday, May 2nd. Three research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company's stock. Based on data from MarketBeat.com, Bicycle Therapeutics has a consensus rating of "Moderate Buy" and an average target price of $25.00.

View Our Latest Analysis on BCYC

Bicycle Therapeutics Trading Down 3.9%

The stock has a 50 day simple moving average of $8.15 and a 200-day simple moving average of $11.12. The firm has a market capitalization of $556.80 million, a P/E ratio of -2.44 and a beta of 1.46.

Bicycle Therapeutics (NASDAQ:BCYC - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The company reported ($0.88) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.86) by ($0.02). The firm had revenue of $9.98 million for the quarter, compared to the consensus estimate of $8.67 million. Bicycle Therapeutics had a negative net margin of 450.64% and a negative return on equity of 27.35%. As a group, sell-side analysts expect that Bicycle Therapeutics plc will post -3.06 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. Barclays PLC boosted its stake in Bicycle Therapeutics by 878.3% in the 4th quarter. Barclays PLC now owns 2,612 shares of the company's stock worth $37,000 after purchasing an additional 2,345 shares during the period. Tocqueville Asset Management L.P. boosted its stake in Bicycle Therapeutics by 24.5% in the 1st quarter. Tocqueville Asset Management L.P. now owns 18,300 shares of the company's stock worth $155,000 after purchasing an additional 3,600 shares during the period. Jane Street Group LLC boosted its stake in Bicycle Therapeutics by 18.9% in the 4th quarter. Jane Street Group LLC now owns 23,991 shares of the company's stock worth $336,000 after purchasing an additional 3,811 shares during the period. Exchange Traded Concepts LLC boosted its stake in Bicycle Therapeutics by 90.3% in the 1st quarter. Exchange Traded Concepts LLC now owns 12,764 shares of the company's stock worth $108,000 after purchasing an additional 6,057 shares during the period. Finally, Bank of America Corp DE boosted its stake in Bicycle Therapeutics by 2.1% in the 4th quarter. Bank of America Corp DE now owns 392,859 shares of the company's stock worth $5,500,000 after purchasing an additional 7,994 shares during the period. 86.15% of the stock is currently owned by institutional investors.

About Bicycle Therapeutics

(Get Free Report)

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.

See Also

Should You Invest $1,000 in Bicycle Therapeutics Right Now?

Before you consider Bicycle Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bicycle Therapeutics wasn't on the list.

While Bicycle Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Don’t Miss These Top 3 Defense Stocks Set To Gain
Triple-Digit Gains: These 4 Nuclear Stocks Have Even More Upside Ahead
3 Made in America Stocks Under $20 You Need to See!

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines